Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Aldesleukin (Primary)
- Indications Malignant melanoma; Renal cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms IL2HD
- 11 Jan 2018 Planned number of patients changed from 19 to 35.
- 11 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2019.
- 11 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Jun 2019.